MedTrace Logo

Short-term Antibiotic Treatment for Unexplained Fever in Solid Cancer Patients With Febrile Neutropenia

NCT01450241 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2013-06-07

No results posted yet for this study

Summary

The purpose of this study is to determine whether short-course antibiotic therapy is safe and effective for the treatment of cancer patients with febrile neutropenia.

Conditions

Interventions

OTHER

Early antibiotic discontinuation

Antibiotic treatment for unexplained febrile neutropenia stopped after 72 hours, regardless of fever

OTHER

Usual practice

Continued antibiotic treatment as accepted by guidelines for febrile neutropenia

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Principal Investigators

  • Mical Paul, MD · Rabin Medical Center

  • Leonard Leibovici, Prof · Rabin Medical Center

  • Dafna Yahav, MD · Rabin Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2014-01-31
Completion
2015-01-31

Countries

  • Israel

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01450241 on ClinicalTrials.gov